Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GNR-127 in Allergic Rhinitis Sensitized to Birch Pollen
NCT07155499Phase 2Completed
- Sponsor
- Generium
- Start
- Oct 2024
- Primary completion
- May 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of GNR-127 in allergic rhinitis (AR), sponsored by Generium. Started Oct 2024; status: completed.
02
Drugs
GNR-127
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT07155499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07155499.